Search Results - "Iderberg, H"

NLX-112, a novel 5-HT1A receptor agonist for the treatment of l-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat by Iderberg, H., McCreary, A.C., Varney, M.A., Kleven, M.S., Koek, W., Bardin, L., Depoortère, R., Cenci, M.A., Newman-Tancredi, A.

“…l-DOPA is the gold-standard treatment for Parkinson's disease (PD), but induces troublesome dyskinesia after prolonged treatment. This is associated with the…”
Get full text

Activity of serotonin 5-HT1A receptor ‘biased agonists’ in rat models of Parkinson's disease and l-DOPA-induced dyskinesia by Iderberg, H., McCreary, A.C., Varney, M.A., Cenci, M.A., Newman-Tancredi, A.

“…Serotonin 5-HT1A receptor agonists reduce l-DOPA-induced dyskinesia (LID) in animal models of Parkinson's disease (PD). Here, we compared the effects of novel…”
Get full text

Animal models of l -DOPA–induced dyskinesia: an update on the current options by Iderberg, H, Francardo, V, Pioli, E.Y

“…Abstract Major limitations to the pharmacotherapy of Parkinson's disease (PD) are the motor complications resulting from l -DOPA treatment. Abnormal…”
Get full text

Sociodemographic determinants and health outcome variation in individuals with type 1 diabetes mellitus: A register-based study by Willers, Carl, Iderberg, Hanna, Axelsen, Mette, Dahlström, Tobias, Julin, Bettina, Leksell, Janeth, Lindberg, Agneta, Lindgren, Peter, Looström Muth, Karin, Svensson, Ann-Marie, Lilja, Mikael

“…Socioeconomic status, origin or demographic attributes shall not determine the quality of healthcare delivery, according to e.g. United Nations and European…”
Get full text

NLX-112, a novel 5-HT 1A receptor agonist for the treatment of l -DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat by Iderberg, H., McCreary, A.C., Varney, M.A., Kleven, M.S., Koek, W., Bardin, L., Depoortère, R., Cenci, M.A., Newman-Tancredi, A.

Get full text

Putaminal upregulation of FosB/ΔFosB-like immunoreactivity in Parkinson's disease patients with dyskinesia by Lindgren, H S, Rylander, D, Iderberg, H, Andersson, M, O'Sullivan, S S, Williams, D R, Lees, A J, Cenci, M A

“…The transcription factor ΔFosB is a mediator of maladaptive neuroplasticity in animal models of Parkinson's disease (PD) and L-DOPA-induced dyskinesia. Using…”
Get more information

The effects of clinical and sociodemographic factors on survival, resource use and lead times in patients with high-grade gliomas: a population-based register study by Bergqvist, Jenny, Iderberg, Hanna, Mesterton, Johan, Henriksson, Roger

“…Background Previous studies indicate an effect of sociodemographic factors on risk for being diagnosed with, as well as on survival of cancer in general. Our…”
Get full text

Predicting clinical outcome and length of sick leave after surgery for lumbar spinal stenosis in Sweden: a multi-register evaluation by Iderberg, Hanna, Willers, Carl, Borgström, Fredrik, Hedlund, Rune, Hägg, Olle, Möller, Hans, Ornstein, Ewald, Sandén, Bengt, Stalberg, Holger, Torevall-Larsson, Hans, Tullberg, Tycho, Fritzell, Peter

“…Purpose Lumbar spinal stenosis (LSS) can be surgically treated, with variable outcome. Studies have linked socioeconomic factors to outcome, but no nation-wide…”
Get full text

ANIMAL MODELS OF L-DOPA-INDUCED DYSKINESIA: AN UPDATE ON THE CURRENT OPTIONS: Neuroscience Disease Models by IDERBERG, H, FRANCARDO, V, PIOLL, E. Y

Get full text

Healthcare resource use, comorbidity, treatment and clinical outcomes for patients with primary intracranial tumors: a Swedish population-based register study by Bergqvist, Jenny, Iderberg, Hanna, Mesterton, Johan, Bengtsson, Nils, Wettermark, Björn, Henriksson, Roger

“…Primary intracranial tumors are relatively uncommon and heterogeneous, which make them challenging to study. We coupled data from unique Swedish…”
Get more information

Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia by Iderberg, H, McCreary, A C, Varney, M A, Cenci, M A, Newman-Tancredi, A

“…Serotonin 5-HT1A receptor agonists reduce L-DOPA-induced dyskinesia (LID) in animal models of Parkinson's disease (PD). Here, we compared the effects of novel…”
Get full text